CAS Number90098-04-7
Synonyms1H-benzimidazol-2-yl(4-chlorophenyl)methanone; 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]propionic acid; Mucosta; Proamipide; 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid; REBAMIPIDEREBAMIPIDE; (R)-2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid; N-(4-Chlorobenzoyl)-3-(2-hydroxyquinolin-4-yl)alanine; N-(4-Chlorobenzoyl)-3-(2-oxo-1,2-dihydro-4-quinolinyl)alanine; REACTIVE ORANGE 122,CINO.ORANGE 122; (±)-a-(p-Chlorobenzamido)-1,2-dihydro-2-oxo-4-quinolinepropionic acid; N-[(4-chlorophenyl)carbonyl]-3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine; MFCD00866895; N-(4-Chlorobenzoyl)-3-(2-oxo-1,2-dihydroquin
Molecular FormulaC19H15ClN2O4
Molecular Weight370.79 (anhydrous basis)
Purity≥98 (HPLC)%
Density1.4±0.1 g/cm3
Boiling Point695.0±55.0 °C at 760 mmHg
Melting Point288-290ºC dec.
Appearancepowder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 90098-04-7 |
| Catalog No. | 2A-9012274 |
| Chinese Name | 瑞巴派特 |
| Synonyms | 1H-benzimidazol-2-yl(4-chlorophenyl)methanone; 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]propionic acid; Mucosta; Proamipide; 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid; 2-(4-Chlorobenzoylamino)-3-(1,2-dihydro-2-oxo-4-quinolyl)propionic acid; 2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid; REBAMIPIDEREBAMIPIDE; (R)-2-(4-chlorobenzamido)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid; N-(4-Chlorobenzoyl)-3-(2-hydroxyquinolin-4-yl)alanine; N-(4-Chlorobenzoyl)-3-(2-oxo-1,2-dihydro-4-quinolinyl)alanine; REACTIVE ORANGE 122,CINO.ORANGE 122; (±)-a-(p-Chlorobenzamido)-1,2-dihydro-2-oxo-4-quinolinepropionic acid; N-[(4-chlorophenyl)carbonyl]-3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine; MFCD00866895; N-(4-Chlorobenzoyl)-3-(2-oxo-1,2-dihydroquin |
| Molecular Formula | C19H15ClN2O4 |
| Molecular Weight | 370.79 (anhydrous basis) |
| Purity | ≥98 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 695.0±55.0 °C at 760 mmHg |
| Melting Point | 288-290ºC dec. |
| Appearance | powder |
| Storage Condition | -20°C Freezer |
| Application | Rebamipide is an endogenous prostaglandin inducer and a free radical scavenger. |
| HTC | 2933790090 |
| PubChem ID | 329824033 |
| MDL Number | MFCD11114396 |
| SMILES | O.OC(=O)C(CC1=CC(=O)Nc2ccccc12)NC(=O)c3ccc(Cl)cc3 |
| InChI | 1S/C19H15ClN2O4.H2O/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15;/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26);1H2 |
| InChI Key | WQRHVBKNEDPECA-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| MSDS | msds/12274_1_90098_04_7.pdf |
| Bioactivity | Rebamipide is an inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger.Target: OthersRebamipide is the first anti-gastric ulcer and antigastritis drug that not only increases endogenous prostaglandin in gastric mucosa but also scavenges oxygen-derived free radicals and inhibits their production. The inhibitory effect of rebamipide on lipid peroxidation induced by a free radical initiator was also demonstrated by the in vitro system using rat gastric mucosal homogenates. These data indicate that rebamipide offers a potential for protection against reactive oxygen- and activated neutrophil-associated gastric mucosal injury by scavenging hydroxyl radical and inhibiting neutrophil activation or lipid peroxidation [1]. Rebamipide can contribute to the management of patients who are taking NSAIDs or are infected with H. pylori. Rebamipide may enhance eradication of H. pylori-infection using standard eradication therapy [2]. Rebamipide is beneficial for obtaining a better quality of ulcer healing and reduction of future ulcer relapse [3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor Research Areas >> Metabolic Disease References [1]. Iinuma, S., et al., In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci, 1998. 43(9 Suppl): p. 35S-39S. [2]. Arakawa, T., et al., Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci, 1998. 43(9 Suppl): p. 5S-13S. [3]. Arakawa, T., et al., Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig Dis Sci, 1995. 40(11): p. 2469-72. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 695.0±55.0 °C at 760 mmHg Melting Point 288-290ºC dec. Molecular Formula C19H15ClN2O4 Molecular Weight 370.786 Flash Point 374.1±31.5 °C Exact Mass 370.072021 PSA 99.26000 LogP 2.90 Vapour Pressure 0.0±2.3 mmHg at 25°C Index of Refraction 1.634 InChIKey ALLWOAVDORUJLA-UHFFFAOYSA-N SMILES O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1 Storage condition -20°C Freezer |
| Use of | Rebamipide is an inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger.Target: OthersRebamipide is the first anti-gastric ulcer and antigastritis drug that not only increases endogenous prostaglandin in gastric mucosa but also scavenges oxygen-derived free radicals and inhibits their production. The inhibitory effect of rebamipide on lipid peroxidation induced by a free radical initiator was also demonstrated by the in vitro system using rat gastric mucosal homogenates. These data indicate that rebamipide offers a potential for protection against reactive oxygen- and activated neutrophil-associated gastric mucosal injury by scavenging hydroxyl radical and inhibiting neutrophil activation or lipid peroxidation [1]. Rebamipide can contribute to the management of patients who are taking NSAIDs or are infected with H. pylori. Rebamipide may enhance eradication of H. pylori-infection using standard eradication therapy [2]. Rebamipide is beneficial for obtaining a better quality of ulcer healing and reduction of future ulcer relapse [3]. Properties Name Rebamipide Synonym More Synonyms Rebamipide Biological Activity Description Rebamipide is an inducer of endogenous prostaglandin and a oxygen-derived free radical scavenger.Target: OthersRebamipide is the first anti-gastric ulcer and antigastritis drug that not only increases endogenous prostaglandin in gastric mucosa but also scavenges oxygen-derived free radicals and inhibits their production. The inhibitory effect of rebamipide on lipid peroxidation induced by a free radical initiator was also demonstrated by the in vitro system using rat gastric mucosal homogenates. These data indicate that rebamipide offers a potential for protection against reactive oxygen- and activated neutrophil-associated gastric mucosal injury by scavenging hydroxyl radical and inhibiting neutrophil activation or lipid peroxidation [1]. Rebamipide can contribute to the management of patients who are taking NSAIDs or are infected with H. pylori. Rebamipide may enhance eradication of H. pylori-infection using standard eradication therapy [2]. Rebamipide is beneficial for obtaining a better quality of ulcer healing and reduction of future ulcer relapse [3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor Research Areas >> Metabolic Disease References [1]. Iinuma, S., et al., In vitro studies indicating antioxidative properties of rebamipide. Dig Dis Sci, 1998. 43(9 Suppl): p. 35S-39S. [2]. Arakawa, T., et al., Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci, 1998. 43(9 Suppl): p. 5S-13S. [3]. Arakawa, T., et al., Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig Dis Sci, 1995. 40(11): p. 2469-72. Chemical & Physical Properties Exact Mass 370.072021 PSA 99.26000 Index of Refraction 1.634 InChIKey ALLWOAVDORUJLA-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Ranolazine | 95635-55-5 | 2A-9012268 |
| Ranolazine dihydrochloride | 95635-56-6 | 2A-9012269 |
| Rapamycin | 53123-88-9 | 2A-9012270 |
| Rasagiline mesylate | 161735-79-1 | 2A-9012271 |
| Razinodil | 30271-85-3 | 2A-9012273 |
| Recainam | 74738-24-2 | 2A-9012275 |
| Red clover P.E. | 2A-303360 | 2A-9012276 |
| Red Clover P.E. | 2A-303361 | 2A-9012277 |
| Redix Ephedrae | 2A-303362 | 2A-9012278 |
| Relomycin | 1404-48-4 | 2A-9012279 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS